Last reviewed · How we verify
NCT05807633: SCOTT
Performance of Novosyn® in Patients Undergoing Uterus Closure in Cesarean Section
trial testing Novosyn® in Cesarean Section Complications in 250 participants. Completed in 1 October 2023.
28 March 2023
Quick facts
| Lead sponsor | Aesculap AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 15 June 2022 |
| Primary completion | 28 March 2023 |
| Estimated completion | 1 October 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Novosyn®
Conditions studied
- Cesarean Section Complications — all drugs for Cesarean Section Complications →
- Cesarean Section; Infection — all drugs for Cesarean Section; Infection →
Sponsor
Aesculap AG — full company profile →
Who can join
18 and older, female only, with Cesarean Section Complications or Cesarean Section; Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to collect clinical data on the use of Novosyn® applied for the uterus closure in cesarean section. Diverse parameters have been selected to assess that the safety and effectiveness of Novosyn® is comparable to published results, where the rate of SSIs in patients undergoing uterus closure in cesarean section was 10.6%.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05807633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cesarean Section Complications
Currently open trials in the same condition.
- NCT07278037 — Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage · recruiting
- NCT05224726 — Platelet Rich Plasma for Uterine Scar · NA · recruiting
- NCT07130747 — Effect of Myofascial Release Versus Deep Friction Massage on Abdominal Recovery and Scar After Cesarean Section · NA · recruiting
- NCT05791630 — The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL) · NA · recruiting
- NCT07049705 — Factors Influencing Bradycardia During Spinal Anesthesia in Obstetric Patients Undergoing Cesarean Section · active not recruiting
Other Aesculap AG trials
Trials by the same sponsor.
- NCT05441618 — Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® · completed
- NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
- NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
- NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
- NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05807633 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05807633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing